Actively Recruiting
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Led by French Africa Pediatric Oncology Group · Updated on 2026-03-02
500
Participants Needed
3
Research Sites
104 weeks
Total Duration
On this page
Sponsors
F
French Africa Pediatric Oncology Group
Lead Sponsor
G
Gustave Roussy, Cancer Campus, Grand Paris
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating new treatment recommendations for children with Acute Lymphoblastic Leukemia ALL through the GFAOP group. This observational study aims to improve outcomes by applying precise protocols and logistical support in developing countries. The study includes both standard and high-risk ALL forms, focusing on achieving high remission rates and long-term survival. The treatment approach proposes anthracycline induction for high-risk cases, including children under 1 year or over 10 years, and uses Endoxan and high-dose Methotrexate in consolidation phases. The study also follows previously established protocols for standard risk patients, aiming to refine and confirm effective treatment strategies for children with ALL. Participants will be monitored for treatment feasibility, adherence, remission rates after induction, and survival without relapse over five years. Assessments include checking correct application of therapy within five weeks and complete remission around day 34 to 42 post-induction. The study expects to evaluate outcomes initially after two years and fully by five years, ensuring comprehensive follow-up and data collection throughout the study period.
CONDITIONS
Brief Title
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children aged 0 to 18 years
- First diagnosis of Acute Lymphoblastic Leukemia (ALL)
- No prior chemotherapy treatment
- Cytology FAB L1 or L2 classification
You will not qualify if you...
- Diagnosis of ALL L3 (Burkitt) type
- Previous chemotherapy treatment for ALL
- Presence of Trisomy 21 (Down syndrome)
Research Team
N
Ndella Ms DIOUF, MD
B
BRENDA Ms MALLON, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here